Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Myeloid 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Colorectal Neoplasms 12Neoplasm Metastasis 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Recurrence Free Survival 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Ovarian Neoplasms 1Lung Neoplasms 1Inflammatory Breast Neoplasms 1Histiocytosis 1Fallopian Tube Neoplasms 1Erythema 1Endometrial Neoplasms 1Edema 1Colonic Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1Advanced Solid Tumors 1

Interventions

Panitumumab 1IFL protocol 1Gemcitabine 1Cetuximab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytosis × Panitumumab × 90 days × Clear all
NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡